ACTA1 and neoplasm: As shown in the schematic of Fig. 3c, the study confirmed that the novel formulation (T-RKP) selectively disrupted α-SMA expression in the tumor core, destabilizing the internal core and eradicating tumor cells without affecting the outer stroma.